Ebola virus disease: Emergence, outbreak and future directions

British Medical Bulletin

Volumn 117, Issue 1, 2016, Pages 95-106

  Lever, Robert A ^a   Whitty, Christopher J M ^a  

^a HOSPITAL FOR TROPICAL DISEASES   (United Kingdom)

Author keywords

control; Ebola; epidemiology; pathogenesis; treatment

Indexed keywords

AMIODARONE; ANTIBIOTIC AGENT; ANTIVIRUS AGENT; BRINCIDOFOVIR; CHIMPANZEE ADENOVIRAL VECTOR VACCINE; CHLOROQUINE; CIDOFOVIR; EBOLA VACCINE; GS 5734; HUMAN IMMUNOGLOBULIN; INTERFERON; LAMIVUDINE; NUCLEOTIDE DERIVATIVE; RECOMBINANT VACCINE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VESICULAR STOMATITIS VACCINE; ZMAPP;

AFRICA; ANTIBIOTIC THERAPY; ANTIVIRAL THERAPY; ARTICLE; BODY FLUID; CADAVER; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); DIARRHEA; EBOLA HEMORRHAGIC FEVER; EBOLAVIRUS; EPIDEMIC; FLUID THERAPY; HEALTH CARE PERSONNEL; HISTORY; HOSPITAL; HUMAN; IMMUNIZATION; INCUBATION TIME; INFECTION CONTROL; MEDICAL SUBJECT HEADINGS; MEDLINE; PHASE 1 CLINICAL TRIAL (TOPIC); POSTHUMOUS CARE; PRIORITY JOURNAL; PUBLIC HEALTH; RISK FACTOR; RISK REDUCTION; UNCERTAINTY; VIROLOGY; VIRUS PATHOGENESIS; VIRUS TRANSMISSION; VIRUS VIRULENCE; WILD ANIMAL; DISEASE OUTBREAKS; HEMORRHAGIC FEVER, EBOLA; PATHOGENICITY; PUBLIC HEALTH SERVICE; TRANSMISSION;

AFRICA, WESTERN; DISEASE OUTBREAKS; EBOLAVIRUS; HEMORRHAGIC FEVER, EBOLA; HUMANS; PUBLIC HEALTH ADMINISTRATION;

EID: 84960412115     PISSN: 00071420     EISSN: 14718391     Source Type: Journal    
DOI: 10.1093/bmb/ldw005     Document Type: Article

References (100)

1. Ebola haemorrhagic fever in Sudan, 1976. Report of a WHO/International Study Team. Bull World Health Organ 1978;56:247-70.
2. Ebola haemorrhagic fever in Zaire. Bull World Health Organ 1978;56:271-93.
3. Heymann DL, Weisfeld JS, Webb PA, et al. Ebola hemorrhagic fever: Tandala, Zaire, 1977-1978. J Infect Dis 1980;142:372-6.
4. Amblard J, Obiang P, Edzang S, et al. Identification of the Ebola virus in Gabon in 1994. Lancet (London, England) 1997;349:181-2.
5. Chippaux J-P. Outbreaks of Ebola virus disease in Africa: The beginnings of a tragic saga. J Venom Anim Toxins Incl Trop Dis 2014;20:44.
6. Pourrut X, Kumulungui B, Wittmann T, et al. The natural history of Ebola virus in Africa. Microbes Infect 2005;7:1005-14.
7. Milleliri JM, Tévi-Benissan C, Baize S, et al. Epidemics of Ebola haemorrhagic fever in Gabon (1994-2002). Epidemiologic aspects and considerations on control measures. Bull Soc Pathol Exot 2004;97:199-205.
8. Le Guenno B, Formenty P, Formentry P, et al. Isolation and partial characterisation of a new strain of Ebola virus. Lancet 1995;345:1271-4.
9. MacNeil A, Farnon EC, Wamala J, et al. Proportion of deaths and clinical features in Bundibugyo Ebola virus infection, Uganda. Emerg Infect Dis 2010;16: 1969-72.
10. Mathiot CC, Fontenille D, Georges AJ, et al. Antibodies to haemorrhagic fever viruses in Madagascar populations. Trans R Soc Trop Med Hyg 1989;83:407-9.
11. Johnson BK, Ocheng D, Gichogo A, et al. Antibodies against haemorrhagic fever viruses in Kenya populations. Trans R Soc Trop Med Hyg 1983;77:731-3.
12. Tomori O, Fabiyi A, Sorungbe A, et al. Viral hemorrhagic fever antibodies in Nigerian populations. Am J Trop Med Hyg 1988;38:407-10.
13. Van der Waals FW, Pomeroy KL, Goudsmit J, et al. Hemorrhagic fever virus infections in an isolated rainforest area of central Liberia. Limitations of the indirect immunofluorescence slide test for antibody screening in Africa. Trop Geogr Med 1986;38:209-14.
14. Gonzalez JP, Josse R, Johnson ED, et al. Antibody prevalence against haemorrhagic fever viruses in randomized representative Central African populations. Res Virol 1989;140:319-31.
15. Becquart P, Wauquier N, Mahlakõiv T, et al. High prevalence of both humoral and cellular immunity to Zaire ebolavirus among rural populations in Gabon. PLoS One 2010;5:e9126.
16. Saéz AM, Weiss S, Nowak K, et al. Investigating the zoonotic origin of the West African Ebola epidemic. EMBO Mol Med 2014;7:17-23.
17. Leroy EM, Kumulungui B, Pourrut X, et al. Fruit bats as reservoirs of Ebola virus. Nature 2005;438:575-6.
18. Jahrling PB, Geisbert TW, Dalgard DW, et al. Preliminary report: isolation of Ebola virus from monkeys imported to USA. Lancet (London, England) 1990;335:502-5.
19. Yaddanapudi K, Palacios G, Towner JS, et al. Implication of a retrovirus-like glycoprotein peptide in the immunopathogenesis of Ebola and Marburg viruses. FASEB J 2006;20:2519-30.
20. Towner JS, Amman BR, Sealy TK, et al. Isolation of genetically diverse Marburg viruses from Egyptian fruit bats. PLoS Pathog 2009;5:e1000536.
21. Olival KJ, Hayman DTS. Filoviruses in bats: current knowledge and future directions. Viruses 2014;6: 1759-88.
22. Leroy EM, Epelboin A, Mondonge V, et al. Human Ebola outbreak resulting from direct exposure to fruit bats in Luebo, Democratic Republic of Congo, 2007. Vector Borne Zoonotic Dis 2009;9:723-8.
23. Baron RC, McCormick JB, Zubeir OA. Ebola virus disease in southern Sudan: hospital dissemination and intrafamilial spread. Bull World Health Organ 1983; 61:997-1003.
24. Kilmarx PH, Clarke KR, Dietz PM, et al. Ebola virus disease in health care workers-Sierra Leone, 2014. Morb Mortal Wkly Rep 2014;63:1168-71.
25. Bausch DG, Towner JS, Dowell SF, et al. Assessment of the risk of Ebola virus transmission from bodily fluids and fomites. J Infect Dis 2007;196(Suppl):S142-7.
26. Ftika L, Maltezou HC. Viral haemorrhagic fevers in healthcare settings. J Hosp Infect 2013;83:185-92.
27. Bah EI, Lamah M-C, Fletcher T, et al. Clinical presentation of patients with Ebola virus disease in Conakry, Guinea. N Engl J Med 2015;372:40-7.
28. Dowell SF, Mukunu R, Ksiazek TG, et al. Transmission of Ebola hemorrhagic fever: A study of risk factors in family members, Kikwit, Democratic Republic of the Congo, 1995. Commission de Lutte contre les Epidémies à Kikwit. J Infect Dis 1999;179(Suppl):S87-91.
29. Formenty P, Leroy EM, Epelboin A, et al. Detection of Ebola virus in oral fluid specimens during outbreaks of Ebola virus hemorrhagic fever in the Republic of Congo. Clin Infect Dis 2006;42:1521-6.
30. Francesconi P, Yoti Z, Declich S, et al. Ebola hemorrhagic fever transmission and risk factors of contacts, Uganda. Emerg Infect Dis 2003;9:1430-7.
31. WHO. Ebola virus disease. World Heal Organ 2014; 7348:1.
32. Ascenzi P, Bocedi A, Heptonstall J, et al. Ebolavirus and Marburgvirus: insight the Filoviridae family. Mol Aspects Med 2008;29:151-85.
33. Hewlett BS, Amola RP. Cultural contexts of Ebola in northern Uganda. Emerg Infect Dis 2003;9:1242-8.
34. Hewlett BS, Epelboin A, Hewlett BL, et al. Medical anthropology and Ebola in Congo: cultural models and humanistic care. Bull Soc Pathol Exot 2005;98:230-6.
35. Schieffelin JS, Shaffer JG, Goba A, et al. Clinical illness and outcomes in patients with Ebola in Sierra Leone. N Engl J Med 2014;371:2092-100.
36. Gire SK, Goba A, Andersen KG, et al. Genomic surveillance elucidates Ebola virus origin and transmission during the 2014 outbreak. Science (80-) 2014;345:1369-72.
37. Johnson E, Jaax N, White J, et al. Lethal experimental infections of rhesus monkeys by aerosolized Ebola virus. Int J Exp Pathol 1995;76:227-36.
38. Deen GF, Knust B, Broutet N, et al. Ebola RNA persistence in semen of Ebola virus disease survivors-preliminary report. N Engl J Med 2015;DOI: 10.1056/NEJMoa1511410[Epub ahead of print].
39. King AMQ, Adams MJ, Carstens EB, et al. Virus Taxonomy: IXth Report of the International Committee on Taxonomy of Viruses: 9780123846846 (8 July 2015, date last accessed).
40. Kuhn JH, Andersen KG, Bào Y, et al. Filovirus RefSeq entries: evaluation and selection of filovirus type variants, type sequences, and names. Viruses 2014;6:3663-82.
41. Olejnik J, Ryabchikova E, Corley RB, et al. Intracellular events and cell fate in filovirus infection. Viruses 2011; 3:1501-31.
42. Booth TF, Rabb MJ, Beniac DR. How do filovirus filaments bend without breaking? Trends Microbiol Elsevier Ltd 2013;21:583-93.
43. Wahl-Jensen V, Kurz SK, Hazelton PR, et al. Role of Ebola virus secreted glycoproteins and virus-like particles in activation of human macrophages. J Virol 2005;79:2413-9.
44. Feldmann H, Volchkov VE, Volchkova VA, et al. The glycoproteins of Marburg and Ebola virus and their potential roles in pathogenesis. Arch Virol Suppl 1999;15:159-69.
45. Zaki SR, Goldsmith CS. Pathologic features of filovirus infections in humans. Curr Top Microbiol Immunol 1999;235:97-116.
46. Feldman H, Geisbert T. Ebola haemorrhagic fever. Lancet 2012;377:849-62.
47. Bray M, Geisbert TW. Ebola virus: The role of macrophages and dendritic cells in the pathogenesis of Ebola hemorrhagic fever. Int J Biochem Cell Biol 2005;37: 1560-6.
48. Baskerville A, Bowen ET, Platt GS, et al. The pathology of experimental Ebola virus infection in monkeys. J Pathol 1978;125:131-8.
49. Villinger F, Rollin PE, Brar SS, et al. Markedly elevated levels of interferon (IFN)-gamma, IFN-Alpha, interleukin (IL)-2, IL-10, and tumor necrosis factor-Alpha associated with fatal Ebola virus infection. J Infect Dis 1999;179(Suppl):S188-91.
50. Falasca L, Agrati C, Petrosillo N, et al. Molecular mechanisms of Ebola virus pathogenesis: focus on cell death. Cell Death Differ 2015;22:1250-9.
51. Georges AJ, Leroy EM, Renaut AA, et al. Ebola hemorrhagic fever outbreaks in Gabon, 1994-1997: epidemiologic and health control issues. J Infect Dis 1999;179(Suppl): S65-75.
52. Baize S, Leroy EM, Georges-Courbot MC, et al. Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients. Nat Med 1999;5:423-6.
53. Marzi A, Engelmann F, Feldmann F, et al. Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates. Proc Natl Acad Sci USA 2013;110:1893-8.
54. Mohamadzadeh M, Chen L, Schmaljohn AL. How Ebola and Marburg viruses battle the immune system. Nat Rev Immunol 2007;7:556-67.
55. Fowler RA, Fletcher T, Fischer WA, et al. Caring for critically ill patients with ebola virus disease. Perspectives from West Africa. Am J Respir Crit Care Med 2014;190:733-7.
56. Lefebvre A, Fiet C, Belpois-Duchamp C, et al. Case fatality rates of Ebola virus diseases: A meta-Analysis of World Health Organization data. Médecine Mal Infect Elsevier Masson SAS 2014;44:412-6.
57. Beeching NJ, Fenech M, Houlihan CF. Ebola virus disease. BMJ 2014;349:g7348.
58. WHO Ebola Response Team. Ebola Virus Disease in West Africa-The first 9 months of the epidemic and forward projections. N Engl J Med 2014; 371:1481-1495.
59. Advisory Committee on Dangerous Pathogens. Public Health England/Department of Health UK. Management of Hazard Group 4 viral haemorrhagic fevers and similar human infectious diseases of high consequence. 2015 https://www.gov.uk/government/publications/viral-haemorrhagic-fever-Algorithm-And-guidance-onmanagement-of-patients (30 November 2015, date last accessed).
60. Kortepeter MG, Bausch DG, Bray M. Basic clinical and laboratory features of filoviral hemorrhagic fever. J Infect Dis 2011;204(Suppl. 3):S810-6.
61. Barry M, Traoré FA, Sako FB, et al. Ebola outbreak in Conakry, Guinea: epidemiological, clinical, and outcome features. Médecine Mal Infect Elsevier Masson SAS 2014;44:491-4.
62. Jiang P, Kargbo D, Jalloh S, et al. Clinical illness and outcomes in patients with Ebola in Sierra Leone. N Engl J Med 2014;371:2092-100.
63. Chertow DS, Kleine C, Edwards JK, et al. Ebola virus disease in West Africa-clinical manifestations and management. N Engl J Med 2014;371:2054-7.
64. Rollin PE, Bausch DG, Sanchez A. Blood chemistry measurements and D-Dimer levels associated with fatal and nonfatal outcomes in humans infected with Sudan Ebola virus. J InfectDis 2007;196(Suppl):S364-71.
65. Varkey JB, Shantha JG, Crozier I, et al. Persistence of Ebola virus in ocular fluid during convalescence. N Engl J Med 2015;372:2423-7.
66. WHO. Persistent Virus in People Recovering From Ebola Virus Disease. Geneva, Switzerland: World Health Organization.
67. Ebola nurse Pauline Cafferkey returns to Glasgow | World News | The Guardian 2015 http://www.theguardian.com/world/2015/nov/12/ebola-nurse-pauline-cafferkey-glasgow. (30November 2015, date last accessed).
68. Broadhurst MJ, Kelly JD, Miller A, et al. ReEBOV Antigen Rapid Test kit for point-of-care and laboratorybased testing for Ebola virus disease: A field validation study. Lancet (London, England) 2015;386:867-74.
69. Whitty CJM, Farrar J, Ferguson N, et al. Infectious disease: Tough choices to reduce Ebola transmission. Nature 2014;515:192-4.
70. Connor MJ, Kraft C, Mehta AK, et al. Successful delivery of RRT in Ebola virus disease. J Am Soc Nephrol 2015;26:31-7.
71. Baize S, Pannetier D, Oestereich L, et al. Emergence of Zaire Ebola Virus Disease in Guinea-preliminary report. N Engl J Med 2014;371:1418-25.
72. Carroll MW, Matthews DA, Hiscox JA, et al. Temporal and spatial analysis of the 2014-2015 Ebola virus outbreak in West Africa. Nature 2015; http://www.ncbi. nlm.nih.gov/pubmed/26083749 (5 September 2015, date last accessed).
73. Gatherer D. The 2014 Ebola virus disease outbreak in West Africa. J Gen Virol 2014;95:1619-24.
74. McCarthy M. Texas healthcare worker is diagnosed with Ebola. BMJ 2014;349:g6200.
75. WHO Ebola Situation Reports | Ebola. http://apps.who. int/ebola/ebola-situation-reports (3 January 2016, date last accessed).
76. Heymann DL. Ebola: learn from the past. Nature 2014;514:299-300.
77. Regules JA, Beigel JH, Paolino KM, et al. A recombinant vesicular Stomatitis Virus Ebola Vaccine-preliminary report. N Engl J Med 2015; doi: 10.1056/NEJMoa1414216.
78. Agnandji ST, Huttner A, Zinser ME, et al. Phase 1 trials of rVSV Ebola vaccine in Africa and Europe-preliminary report. N Engl J Med 2015; doi: 10.1056/NEJMoa1502924.
79. Ledgerwood JE, DeZure AD, Stanley DA, et al. Chimpanzee Adenovirus Vector Ebola Vaccine-Preliminary Report. N Engl J Med 2014; doi: 10.1056/NEJMoa1410863.
80. Rampling T, Ewer K, Bowyer G, et al. A Monovalent Chimpanzee Adenovirus Ebola Vaccine-Preliminary Report. N Engl J Med 2015; doi: 10.1056/NEJMoa1411627.
81. Sullivan NJ, Martin JE, Graham BS, et al. Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule. Nat Rev Microbiol 2009;7:393-400.
82. Sullivan NJ, Geisbert TW, Geisbert JB, et al. Accelerated vaccination for Ebola virus haemorrhagic fever in nonhuman primates. Nature 2003;424:681-4.
83. Stanley DA, Honko AN, Asiedu C, et al. Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. Nat Med 2014;20:1126-9.
84. Bausch DG. One step closer to an Ebola virus vaccine. N Engl J Med 2014; doi: 10.1056/NEJMe1414305.
85. Henao-Restrepo AM, Longini IM, Egger M, et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet 2015;386:857-66.
86. Coltart CEM, Johnson AM, Whitty CJM. Role of healthcare workers in early epidemic spread of Ebola: policy implications of prophylactic compared to reactive vaccination policy in outbreak prevention and control. BMC Med 2015;13:271.
87. Jones SM, Feldmann H, Ströher U, et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med 2005;11: 786-90.
88. Macneil A, Reed Z, Rollin PE. Serologic crossreactivity of human IgM and IgG antibodies to five species of Ebola virus. PLoS Negl Trop Dis 2011;5: e1175.
89. Hensley LE, Mulangu S, Asiedu C, et al. Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus Species. PLoS Pathog 2010; 6:e1000904.
90. Wong G, Kobinger GP. Backs against the Wall: novel and existing strategies used during the 2014-2015 Ebola virus outbreak. Clin Microbiol Rev 2015;28: 593-601.
91. Mupapa K, Massamba M, Kibadi K, et al. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee. J Infect Dis 1999;179 (Suppl):18-23.
92. WHO. WHO Meeting of the Scientific and Technical Advisory Committee on Ebola Experimental Interventions-Briefing Note. Geneva, Switzerland: World Health Organization.
93. Bishop BM. Potential and emerging treatment options for Ebola virus disease. Ann Pharmacother 2015;49: 196-206.
94. Hensley LE, Dyall J, Olinger GG, et al. Lack of effect of lamivudine on Ebola virus replication. Emerg Infect Dis 2015;21:550-2.
95. Kupferschmidt K, Cohen J. Infectious diseases. Ebola drug trials lurch ahead. Science 2015;347:701-2.
96. Lyon GM, Mehta AK, Varkey JB, et al. Clinical care of two patients with Ebola virus disease in the United States. N Engl J Med 2014;371:2402-9.
97. Geisbert TW, Lee ACH, Robbins M, et al. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: A proofof-concept study. Lancet 2010;375:1896-05.
98. Kraft CS, Hewlett AL, Koepsell S, et al. The use of TKM-100802 and convalescent plasma in 2 patients with Ebola virus disease in the United States. Clin Infect Dis 2015;61:496-502.
99. Researchers Put Brakes on Study of Tekmira Ebola Drug in West Africa-WSJ. http://www.wsj.com/articles/researchersput-brakes-on-study-of-Tekmira-ebola-drug-in-west-Africa-1434732833 (27 December 2015, date last accessed).
100. Gilead Provides Update on Investigational Compound, GS-5734, for the Treatment of Ebola Virus Disease | Gilead. http://www.gilead.com/news/press-releases/2015/10/gilead-provides-update-on-investigationalcompound-gs5734-for-The-Treatment-of-ebola-virusdisease (27 December 2015, date last accessed).